7,354 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by Point72 DIFC Ltd

Point72 DIFC Ltd purchased a new stake in Biohaven Ltd. (NYSE:BHVN) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,354 shares of the company’s stock, valued at approximately $368,000.

Several other large investors have also recently modified their holdings of the business. nVerses Capital LLC bought a new stake in shares of Biohaven in the third quarter worth $50,000. Redwood Wealth Management Group LLC bought a new stake in shares of Biohaven in the 2nd quarter valued at about $61,000. Values First Advisors Inc. bought a new position in shares of Biohaven during the third quarter worth about $78,000. US Bancorp DE lifted its stake in shares of Biohaven by 57.1% in the third quarter. US Bancorp DE now owns 2,173 shares of the company’s stock worth $109,000 after acquiring an additional 790 shares during the period. Finally, KBC Group NV boosted its holdings in Biohaven by 24.5% in the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after acquiring an additional 443 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on BHVN shares. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price target (up previously from $58.00) on shares of Biohaven in a report on Wednesday. HC Wainwright restated a “buy” rating and issued a $59.00 target price on shares of Biohaven in a report on Tuesday, November 26th. Robert W. Baird increased their price target on Biohaven from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, September 23rd. UBS Group dropped their price objective on Biohaven from $55.00 to $54.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. Finally, Sanford C. Bernstein upped their target price on Biohaven from $55.00 to $66.00 and gave the company an “outperform” rating in a research report on Tuesday, September 24th. Thirteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Biohaven currently has a consensus rating of “Buy” and an average target price of $63.00.

Insider Transactions at Biohaven

In other news, Director Gregory Bailey bought 5,000 shares of the stock in a transaction dated Tuesday, September 24th. The stock was bought at an average price of $44.19 per share, for a total transaction of $220,950.00. Following the completion of the acquisition, the director now directly owns 1,620,071 shares in the company, valued at approximately $71,590,937.49. This trade represents a 0.31 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director John W. Childs purchased 21,052 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were purchased at an average price of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the acquisition, the director now owns 21,052 shares of the company’s stock, valued at $999,970. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Company insiders own 16.00% of the company’s stock.

Biohaven Trading Up 3.0 %

BHVN opened at $44.80 on Friday. Biohaven Ltd. has a 1-year low of $26.80 and a 1-year high of $62.21. The company has a market cap of $4.53 billion, a price-to-earnings ratio of -4.79 and a beta of 1.24. The company’s fifty day moving average price is $49.37 and its two-hundred day moving average price is $41.60.

Biohaven (NYSE:BHVN) last posted its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03). As a group, equities analysts forecast that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.